Children's Hospital Oakland Research Institute, 5700 Martin Luther King Jr, Way, Oakland, CA 94609, USA.
BMC Biochem. 2012 Jun 7;13:8. doi: 10.1186/1471-2091-13-8.
Unsaturated fatty acids are susceptible to oxidation and damaged chains are removed from glycerophospholipids by phospholipase A(2). De-acylated lipids are then re-acylated by lysophospholipid acyltransferase enzymes such as LPCAT1 which catalyses the formation of phosphatidylcholine (PC) from lysoPC and long-chain acyl-CoA.
Activity of LPCAT1 is inhibited by Ca(2+), and a Ca(2+)-binding motif of the EF-hand type, EFh-1, was identified in the carboxyl-terminal domain of the protein. The residues Asp-392 and Glu-403 define the loop of the hairpin structure formed by EFh-1. Substitution of D(392) and E(403) to alanine rendered an enzyme insensitive to Ca(2+), which established that Ca(2+) binding to that region negatively regulates the activity of the acyltransferase amino-terminal domain. Residue Cys-211 of the conserved motif III is not essential for catalysis and not sufficient for sensitivity to treatment by sulfhydryl-modifier agents. Among the several active cysteine-substitution mutants of LPCAT1 generated, we identified one to be resistant to treatment by sulfhydryl-alkylating and sulfhydryl-oxidizer agents.
Mutant forms of LPCAT1 that are not inhibited by Ca(2+) and sulfhydryl-alkylating and -oxidizing agents will provide a better understanding of the physiological function of a mechanism that places the formation of PC, and the disposal of the bioactive species lysoPC, under the control of the redox status and Ca(2+) concentration of the cell.
不饱和脂肪酸容易氧化,甘油磷脂中的受损链通过磷脂酶 A(2)被移除。然后,脱酰基脂质被溶血磷脂酰基转移酶(如 LPCAT1)重新酰化,该酶将溶血磷脂酰胆碱(lysoPC)和长链酰基辅酶 A 催化形成磷脂酰胆碱 (PC)。
LPCAT1 的活性受 Ca(2+)抑制,在蛋白质的羧基末端结构域中发现了 EF 手型的 Ca(2+)结合基序 EFh-1。残基 Asp-392 和 Glu-403 定义了 EFh-1 形成的发夹结构的环。将 D(392)和 E(403)替换为丙氨酸会使酶对 Ca(2+)不敏感,从而确定 Ca(2+)与该区域的结合对酰基转移酶氨基末端结构域的活性起负调控作用。保守基序 III 中的残基 Cys-211 对催化作用不是必需的,也不足以对巯基修饰剂的处理敏感。在生成的 LPCAT1 的几个活性半胱氨酸取代突变体中,我们鉴定出一个对巯基烷化剂和巯基氧化剂的处理具有抗性。
不受 Ca(2+)和巯基烷化剂和氧化剂抑制的 LPCAT1 突变体形式将更好地理解将 PC 的形成和生物活性物质 lysoPC 的处理置于细胞的氧化还原状态和 Ca(2+)浓度控制下的机制的生理功能。